EVMN Latest Press Releases

-- April 6, 2026 --

Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine Business Wire 9:00 AM

-- March 5, 2026 --

Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights Business Wire 4:01 PM

-- February 12, 2026 --

Evommune Announces $125 Million Private Placement Business Wire 8:30 PM

-- February 10, 2026 --

Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis Business Wire 7:30 AM

-- December 11, 2025 --

Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update Business Wire 4:05 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software